Pieris Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Note 3 - Revenue - Potential Milestone Payments Received (Details) - Collaborative Arrangement [Member] $ in Millions	Sep. 30, 2022 USD ($)
Research And Development Milestone Payments [Member]
milestone	$ 2,496
Research And Development Milestone Payments [Member] \| Astra Zeneca A B [Member]
milestone	702
Research And Development Milestone Payments [Member] \| Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member]
milestone	118
Research And Development Milestone Payments [Member] \| Seattle Genetics Inc. [Member]
milestone	754
Research And Development Milestone Payments [Member] \| Boston Pharmaceuticals [Member]
milestone	88
Research And Development Milestone Payments [Member] \| Genentech [Member]
milestone	834
Sales Milestone Payments [Member]
milestone	5,328
Sales Milestone Payments [Member] \| Astra Zeneca A B [Member]
milestone	3,925
Sales Milestone Payments [Member] \| Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member]
milestone	88
Sales Milestone Payments [Member] \| Seattle Genetics Inc. [Member]
milestone	450
Sales Milestone Payments [Member] \| Boston Pharmaceuticals [Member]
milestone	265
Sales Milestone Payments [Member] \| Genentech [Member]
milestone	$ 600